Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Research article

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis

Authors: Pravesh Kumar Bundhun, Feng Huang

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

Background

Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied. We aimed to systematically carry out a direct comparison of outcomes observed with prasugrel versus clopidogrel following PCI.

Methods

Common online searched databases (The Cochrane library, EMBASE, MEDLINE and Google scholar) were used to retrieve relevant publications. Primary endpoints were the adverse cardiovascular outcomes. Secondary outcomes were the bleeding events. This analysis was carried out by RevMan 5.3, whereby odds ratios (OR) and 95% confidence intervals (CI) were considered as the statistical parameters.

Results

Eight studies with a total number of 18,122 participants were included in this direct analysis. Prasugrel was associated with significantly lower adverse cardiovascular outcomes in comparison to clopidogrel following PCI. All-cause mortality, myocardial infarction, stroke, stent thrombosis and major adverse cardiac events were all significantly lower with prasugrel (OR: 0.47, 95% CI: 0.35–0.63; P = 0.0001), (OR: 0.68, 95% CI: 0.57–0.80; P = 0.00001), (OR: 0.60, 95% CI: 0.38–0.96; P = 0.03), (OR: 0.46, 95% CI: 0.30–0.72; P = 0.0006) and (OR: 0.61, 95% CI: 0.53–0.70; P = 0.00001) respectively.
When the bleeding outcomes were analyzed, Thrombolysis in Myocardial Infarction (TIMI) defined major and minor bleeding were not significantly different (OR: 0.91, 95% CI: 0.66–1.27; P = 0.59) and (OR: 1.16, 95% CI: 0.85–1.59; P = 0.35) respectively. However, the combined ‘all bleeding events’ was significantly higher with prasugrel (OR: 1.32, 95% CI: 1.03–1.70; P = 0.03), but when patients with STEMI and those undergoing elective PCI were separately analyzed, no significant difference in overall bleeding was observed.

Conclusion

Adverse cardiovascular outcomes were significantly lower with the use of prasugrel in comparison to clopidogrel following PCI. In addition, TIMI defined major and minor bleeding were not significantly different showing prasugrel to be well-tolerated following PCI especially in patients with acute coronary syndrome.
Literature
1.
go back to reference Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY. Did Prasugrel and Ticagrelor offer the same benefit in patients with acute coronary syndromes after percutaneous coronary interventions compared to Clopidogrel? Insights from randomized clinical trials, registries and meta-analysis. Curr Pharm Des. 2018; https://doi.org/10.2174/1381612824666180108121834. Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY. Did Prasugrel and Ticagrelor offer the same benefit in patients with acute coronary syndromes after percutaneous coronary interventions compared to Clopidogrel? Insights from randomized clinical trials, registries and meta-analysis. Curr Pharm Des. 2018; https://​doi.​org/​10.​2174/​1381612824666180​108121834.
2.
go back to reference Cherepanov V, Fortmann SD, Kim MH, Marciniak TA, Litvinov O, Mihalev K, Serebruany VL. Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration adverse event reporting system. Eur Heart J Cardiovasc Pharmacother. 2017; https://doi.org/10.1093/ehjcvp/pvx038. Cherepanov V, Fortmann SD, Kim MH, Marciniak TA, Litvinov O, Mihalev K, Serebruany VL. Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration adverse event reporting system. Eur Heart J Cardiovasc Pharmacother. 2017; https://​doi.​org/​10.​1093/​ehjcvp/​pvx038.
3.
go back to reference Tarantini G, Ueshima D, D'Amico G, Masiero G, Musumeci G, Stone GW, Brener SJ. Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: a systematic review and meta-analysis. Am Heart J. 2018;195:78–85.CrossRefPubMed Tarantini G, Ueshima D, D'Amico G, Masiero G, Musumeci G, Stone GW, Brener SJ. Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: a systematic review and meta-analysis. Am Heart J. 2018;195:78–85.CrossRefPubMed
4.
go back to reference Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost. 2013;109(1):93–101.CrossRefPubMed Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost. 2013;109(1):93–101.CrossRefPubMed
5.
go back to reference Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2015;116(5):809–17.CrossRefPubMed Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2015;116(5):809–17.CrossRefPubMed
6.
go back to reference Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis. 2013;36(3):223–32.CrossRefPubMed Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis. 2013;36(3):223–32.CrossRefPubMed
7.
go back to reference Chen HB, Zhang XL, Liang HB, Liu XW, Zhang XY, Huang BY, Xiu J. Meta-analysis of randomized controlled trials comparing risk of major adverse cardiac events and bleeding in patients with Prasugrel versus Clopidogrel. Am J Cardiol. 2015;116(3):384–92.CrossRefPubMed Chen HB, Zhang XL, Liang HB, Liu XW, Zhang XY, Huang BY, Xiu J. Meta-analysis of randomized controlled trials comparing risk of major adverse cardiac events and bleeding in patients with Prasugrel versus Clopidogrel. Am J Cardiol. 2015;116(3):384–92.CrossRefPubMed
8.
go back to reference Kikkert WJ, van Geloven N, van der Laan MH, Vis MM, Baan J Jr, Koch KT, Peters RJ, de Winter RJ, Piek JJ, Tijssen JG, Henriques JP. The prognostic value of bleeding academic research consortium (BARC)-defined bleedingcomplications in ST-segment elevation myocardial infarction: a comparison with the TIMI (thrombolysis in myocardial infarction), GUSTO (global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries), and ISTH (international society on thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol. 2014;63(18):1866–75.CrossRefPubMed Kikkert WJ, van Geloven N, van der Laan MH, Vis MM, Baan J Jr, Koch KT, Peters RJ, de Winter RJ, Piek JJ, Tijssen JG, Henriques JP. The prognostic value of bleeding academic research consortium (BARC)-defined bleedingcomplications in ST-segment elevation myocardial infarction: a comparison with the TIMI (thrombolysis in myocardial infarction), GUSTO (global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries), and ISTH (international society on thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol. 2014;63(18):1866–75.CrossRefPubMed
10.
go back to reference Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral
11.
go back to reference Brener SJ, Oldroyd KG, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, Gibson CM, Stone GW. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Am J Cardiol. 2014;113(9):1457–60.CrossRefPubMed Brener SJ, Oldroyd KG, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, Gibson CM, Stone GW. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Am J Cardiol. 2014;113(9):1457–60.CrossRefPubMed
12.
go back to reference Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E. JUMBO-TIMI 26 investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111(25):3366–73.CrossRefPubMed Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E. JUMBO-TIMI 26 investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111(25):3366–73.CrossRefPubMed
13.
go back to reference Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Nakamura M. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patientswith acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78(7):1684–92.CrossRefPubMed Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Nakamura M. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patientswith acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78(7):1684–92.CrossRefPubMed
14.
go back to reference Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. PRINCIPLE-TIMI 44 investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to Clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116(25):2923–32.CrossRefPubMed Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. PRINCIPLE-TIMI 44 investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to Clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116(25):2923–32.CrossRefPubMed
15.
go back to reference Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Qayyum A, Pedersen F, Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (thrombocytes and IndividuaLization of ORal antiplatelet therapy in percutaneous coronaryintervention) randomized trial. Platelets. 2014;25(7):506–12.CrossRefPubMed Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Qayyum A, Pedersen F, Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (thrombocytes and IndividuaLization of ORal antiplatelet therapy in percutaneous coronaryintervention) randomized trial. Platelets. 2014;25(7):506–12.CrossRefPubMed
16.
go back to reference Jackson LR 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, Baker BA, Effron M, Peterson ED, Wang TY. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of Clopidogrel versus Prasugrel from the TRANSLATE-ACS study. JACC Cardiovasc Interv. 2015;8(14):1880–9.CrossRefPubMed Jackson LR 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, Baker BA, Effron M, Peterson ED, Wang TY. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of Clopidogrel versus Prasugrel from the TRANSLATE-ACS study. JACC Cardiovasc Interv. 2015;8(14):1880–9.CrossRefPubMed
17.
go back to reference Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-elutingstents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing ElectiveStent placement on Clopidogrel to guide alternative therapy with Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159–64.CrossRefPubMed Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-elutingstents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing ElectiveStent placement on Clopidogrel to guide alternative therapy with Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159–64.CrossRefPubMed
18.
go back to reference Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM. TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary interventionfor ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31.CrossRefPubMed Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM. TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary interventionfor ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31.CrossRefPubMed
19.
go back to reference Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish coronary angiography and angioplasty registry [SCAAR]). Am J Cardiol. 2014;113(1):64–9.CrossRefPubMed Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish coronary angiography and angioplasty registry [SCAAR]). Am J Cardiol. 2014;113(1):64–9.CrossRefPubMed
20.
go back to reference Bundhun PK, Shi JX, Huang F. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. BMC Pharmacol Toxicol. 2017;18(1):80.CrossRefPubMedPubMedCentral Bundhun PK, Shi JX, Huang F. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. BMC Pharmacol Toxicol. 2017;18(1):80.CrossRefPubMedPubMedCentral
21.
go back to reference Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation. 2013;128(8):823–33.CrossRefPubMed Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation. 2013;128(8):823–33.CrossRefPubMed
22.
go back to reference Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost. 2010;103(1):213–23.CrossRefPubMed Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost. 2010;103(1):213–23.CrossRefPubMed
23.
go back to reference Khatri S, Pierce T. Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a veterans affairs population. Am J Health Syst Pharm. 2015;72(17 Suppl 2):S98–S103.CrossRefPubMed Khatri S, Pierce T. Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a veterans affairs population. Am J Health Syst Pharm. 2015;72(17 Suppl 2):S98–S103.CrossRefPubMed
24.
go back to reference Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM, TIMI Study Group. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronarysyndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess improvement in therapeutic outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-thrombolysis in myocardial infarction (TIMI) 38 substudy. Am Heart J. 2009;158(3):e21–6.CrossRefPubMed Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM, TIMI Study Group. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronarysyndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess improvement in therapeutic outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-thrombolysis in myocardial infarction (TIMI) 38 substudy. Am Heart J. 2009;158(3):e21–6.CrossRefPubMed
25.
go back to reference Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011;4(4):403–10.CrossRefPubMed Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011;4(4):403–10.CrossRefPubMed
26.
go back to reference Lalor N, Rodríguez L, Elissamburu P, Filipini E, Conde D, Nau G, Cura F, Trivi M. Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty. Medicina (B Aires). 2015;75(4):207–12. Lalor N, Rodríguez L, Elissamburu P, Filipini E, Conde D, Nau G, Cura F, Trivi M. Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty. Medicina (B Aires). 2015;75(4):207–12.
27.
go back to reference Wang A, Lella LK, Brener SJ. Efficacy and safety of Prasugrel compared with Clopidogrel for patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Ther. 2016;23(6):e1637–43.CrossRefPubMed Wang A, Lella LK, Brener SJ. Efficacy and safety of Prasugrel compared with Clopidogrel for patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Ther. 2016;23(6):e1637–43.CrossRefPubMed
28.
go back to reference Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presentingwith ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.CrossRefPubMed Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presentingwith ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.CrossRefPubMed
29.
go back to reference Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Ettinger SM, Ganiats TG, Philippides GJ, Jacobs AK, Halperin JL, Albert NM, Creager MA, DeMets D, Guyton RA, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61(23):e179–347.CrossRefPubMed Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Ettinger SM, Ganiats TG, Philippides GJ, Jacobs AK, Halperin JL, Albert NM, Creager MA, DeMets D, Guyton RA, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61(23):e179–347.CrossRefPubMed
30.
go back to reference Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabrò P, Mauro C, Pieretti G, Coppola A, Nicoletti G, Rizzo MR, Paolisso G, Barbieri M. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culpritobstructive and multivessel non obstructive-coronary-stenosis. Diabetol Metab Syndr. 2018;10:1.CrossRefPubMedPubMedCentral Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabrò P, Mauro C, Pieretti G, Coppola A, Nicoletti G, Rizzo MR, Paolisso G, Barbieri M. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culpritobstructive and multivessel non obstructive-coronary-stenosis. Diabetol Metab Syndr. 2018;10:1.CrossRefPubMedPubMedCentral
31.
go back to reference Marfella R, Sardu C, Calabrò P, Siniscalchi M, Minicucci F, Signoriello G, Balestrieri ML, Mauro C, Rizzo MR, Paolisso G, Barbieri M. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: effects of incretin treatment. Diabetes Obes Metab. 2018;20(3):723–9.CrossRefPubMed Marfella R, Sardu C, Calabrò P, Siniscalchi M, Minicucci F, Signoriello G, Balestrieri ML, Mauro C, Rizzo MR, Paolisso G, Barbieri M. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: effects of incretin treatment. Diabetes Obes Metab. 2018;20(3):723–9.CrossRefPubMed
Metadata
Title
Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis
Authors
Pravesh Kumar Bundhun
Feng Huang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0820-6

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue